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Abstract 
To investigate the blood glucose lowering effect of the seed powder of T. foenum-graecum 
Linn (Papilionaceae) in normal and alloxan-induced diabetic rabbits. The blood glucose 
lowering effect of the seed powder was determined in normal and alloxan-induced (100 
mg/kg, i.v.) diabetic rabbits, after oral administration of doses of 50, 100 and 150 mg/kg 
body weight. Blood samples were collected from the marginal ear vein before and also at 4, 
6, 8, 10, 12, 16, 18, 20 and 24 h after drug administration and blood glucose was analysed by 
Nelson-Somogyi's method using a visible spectrophotometer. The data was compared 
statistically by using Student's t-test. The seed powder of T. foenum-graecum produced a 
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dose-dependent reduction in blood glucose of both normal and diabetic rabbits and 
comparable with that of standard drug, glibenclamide. The results indicate a prolonged 
action in reduction of blood glucose by T. foenum-graecum and the mode of action of the 
active compound (s) of T. foenum-graecum is probably mediated through enhanced 
secretion of insulin from the -cells of Langerhans or through extrapancreatic mechanism. 
The present study clearly indicated a significant anti-diabetic activity with the seed powder 
of T. foenum-graecum and supported the traditional usage of the seed powder by Ayurvedic 
physicians for the control of diabetes.  
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1. Introduction 
Diabetes mellitus is a metabolic disease that emerges as one of the leading diseases all over the 
World. Global statistics on diabetes indicate that approximately 50% of diabetic population live in 
Asia. Recent estimates indicate that approximately 366 million people are affected with diabetes, 
with 90% suffering from T2D and by the year 2030, this number is expected to increase to 552 
million [1]. Increased consumption of high-calorie fatty food associated with decreased physical 
activity also contributes to the pandemic of T2D [2]. The current therapeutic options such as diet 
modification, oral hypoglycaemic agents (OHA) and insulin treatment have their own limitations in 
treating T2D. Ayurveda, the indigenous Indian system of medicine, has offered many herbal 
medicines for the treatment of diabetes or ‘madhumeha’. Although, some of these traditional 
herbal medicines have been experimentally evaluated, search for new anti-diabetic drugs 
continues. [3-9].  
Trigonella foenum-graecum Linn (Papilionaceae) commonly referred as fenugreek is a herb that 
belongs to the family, Papilionaceae and indigenous to the Indian sub-continent and Eastern 
Mediterranean [10]. In Ayurveda, the seeds and leaves of T. foenum-graecum have been regarded 
as carminative, tonic, aphrodisiac and used to treat diabetes and cardiovascular disorders [11-13]. 
Its dried ripe seeds are known as Trigonella seeds or fenugreek seeds. The seeds possess pungent 
aromatic properties [14] and often used as a spice in food preparations to enhance its flavor [15], 
while the leaves are widely consumed as a leafy vegetable in India [16]. A converging point of 
evidence from earlier investigations on the seed extract and leaf extracts of T. foenum-graecum 
revealed significant anti-diabetic effects in both animals [17-22] and humans [16, 23-25]. The 
pharmacological effects of T. foenum-graecum are attributed to a range of bioactive compounds 
such as polyphenols, steroids, lipids, alkaloids, saponins, flavonoids, hydrocarbons, carbohydrates, 
galactomannan fiber, and amino acids. More recently, Sharma and colleagues have reported that 
the chronic administration of fenugreek seed extract showed protective effect against diabetes 
induced oxidative DNA damage in alloxan-induced diabetic rats [26]. Furthermore, it has also been 
demonstrated that fenugreek seed extract, protects brain tissue by mitigating oxidative stress 
induced by alloxan-exposed diabetic rats [27]. Diosgenin saponin is considered the most bioactive 
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substance of T. foenum-graecum seeds and found to have anti-oxidative effects and plays a pivotal 
role in improving the diabetic condition in several in vivo and in vitro models [28].  
However, some clinical trials did not show any benefit from fenugreek [29, 30]. The seeds of T. 
foenum-graecum are also known to possess antiulcer [31], hepatoprotective [32] and 
hypocholesterolaemic effects [33, 34]. Nevertheless, the seed powder of T. foenum-graecum is 
being prescribed by Ayurvedic physicians for the treatment of diabetes [35]. However, there are 
only meager reports on the direct usage of the seed powder. Therefore, the present study was 
aimed to study the influence of the seed powder of T. foenum-graecum on the fasting blood 
glucose in normal and alloxan diabetic rabbits.  
2. Materials and Methods 
2.1 Plant Material  
The seeds of T. foenum-graecum were bought at the local market, botanically authenticated 
and a voucher specimen was preserved for future reference. Seeds were cleaned, dried for 4 
hours and then grounded to fine powder. 
2.2 Chemicals Used 
Glibenclamide was a generous gift sample by Hoechst Pharmaceuticals, Mumbai whereas 
alloxan was purchased from Sigma-Aldrich, St. Louis, MO, USA. All other reagents used were of 
analytical grade and purchased from Loba-Chemie, Mumbai, India.  
2.3 Animals  
A total of fifty (50) adult albino rabbits (B.N. Ghosh & Co., Kolkata, India) weighing 1.5-2 kg of 
both sexes were chosen for investigation. The rabbits were maintained in a well-ventilated animal 
house with an ambient temperature (24 ± 2 ºC) and relative humidity (50-60%) with 12-h light and 
dark cycle. The rabbits were acclimatized to the laboratory environment for 1 week before the 
start of the experiments and fed with standard diet and water ad libitum. They were fasted for 
overnight, allowing only access to water, and deprived of both food and water during the 24-hour 
monitoring cycle of the experiment after treatment with either the drug or distilled water 
(control) to reduce plasma volume changes. For each treatment the same procedure has been 
followed. The local Institutional Animal Ethics Committee has approved the use and handling of 
the animals in the experimental protocol (Regd. No. 516/01/A/CPCSEA) following the guidelines of 
the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), 
Government of India.  
2.4 Experimental Design and Treatments 
The rabbits were matched in weight and split into 10 groups, each consisting of five rabbits. 
Groups I, II and III were respectively given the seed powder of T. foenum-graecum (suspended in 
distilled water) by oral gavage at doses of 50, 100 and 150 mg/kg body weight. Glibenclamide was 
given by oral gavage in Group IV (positive control) at a dose of 40 μg/kg body weight in a total 
volume of 3 mL for each rabbit. Group V used as normal control and administered with 3 mL of 
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distilled water. Diabetes was induced in Groups VI to X by injecting 100 mg/kg of alloxan into the 
marginal ear vein after determining the baseline blood glucose levels. Two weeks post-alloxan 
treatment when stable diabetes was achieved, rabbits with blood glucose levels above 300 mg/dl 
were selected for the experiments. Animals in groups VI, VII & VIII, received by oral gavage, the 
seed powder of T. foenum-graecum at doses of 50, 100 and 150 mg/kg respectively. Group IX 
(positive control) received glibenclamide by oral gavage at a dose of 40 g/kg while group X 
served as diabetic control. 
2.5 Blood Collection and Analytical Procedure 
Approximately 0.3 mL of blood samples were drawn from the marginal ear vein of rabbits 
before and also at 4, 6, 8, 10, 12, 16, 18, 20 & 24 h after treatment. The samples were collected in 
glass vials that contained a small amount of an anti-coagulant mixture of potassium oxalate and 
sodium fluoride. Separation of plasma was done by centrifuging at 2000 rpm and stored at -20°C 
until analysis for glucose by Nelson-Somogyi's method [36, 37] using a visible spectrophotometer. 
2.6 Data and Statistical Analysis 
Data was presented as a means ± SEM. To examine the quantitative differences among the 
experimental groups, the respective data were subjected to analysis of variance (ANOVA) using 
GraphPad Prism-7.03 (GraphPad Software Inc., California, CA) statistical programme. Post hoc 
comparisons were made using Student’s unpaired t-test. In all tests, p<0.05 value was used as the 
criterion for statistical significance. 
3. Results  
3.1 T. foenum-graecum Lowered Blood Glucose in Normal Rabbits 
In normal rabbits the seed powder of T. foenum-graecum produced dose-dependent 
hypoglycemia. A maximum reduction in blood glucose of 9.4% (105.8 vs 95.4; 6 h), 26.9% (106.4 vs 
77.8; 8 h, p<0.01), and 39.2% (108.2 vs 65.8; 10 h, p<0.001) with doses of 50, 100 and 150 mg/kg 
body weight respectively (Table 1) and the glucose reduction tendency continued up to 24 hours 
with 100 and 150 mg/kg doses. Glibenclamide (40 g/kg) produced a significant (p<0.01) 
reduction of blood glucose relative with control (31.9%, 8 h).  
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3.2 T. foenum-graecum Lowered Blood Glucose in Diabetic Rabbits 
The diabetic rabbits treated with T. foenum-graecum also displayed a dose-dependent 
decrease in blood glucose. However, a higher reduction of blood glucose was seen in the diabetic 
rabbits compared with the normal rabbits. A significant reduction (p<0.001) of blood glucose of 
12.4% (316.5 vs 277.2; 6 h), 32.5% (312.8 vs 211.0; 8 h) and 44.6% (312.8 vs 173.5; 8 h) 
respectively was seen with T. foenum-graecum at doses of 50, 100 and 150 mg/kg body weight 
(Table 2). Although less significant, the glucose lowering tendency continued up to 20 hours with 
all the doses of T. foenum-graecum. Glibenclamide (40 g/kg) resulted in a significant reduction 
(p<0.001) in blood glucose at 8 h (34.1%) compared to diabetic control.  
4. Discussion  
Diabetes mellitus is probably the biggest rising metabolic condition in the world, and as 
understanding of this complex condition is advanced, there is an increasing need for more 
effective treatment [9, 36]. Traditional plant medicinal products are used for a variety of diabetic 
complications around the world. Studying such medicines could give a natural key for opening the 
potential pharmacy of a diabetologist. The seeds of T. foenum-graecum are commonly used for 
managing diabetes in India. For this reason, the seed powder of T. foenum-graecum was tested, 
and the results verified the conventional indications as well. The findings of our experiments on 
rabbits are also substantiated by earlier investigations [20, 22, 37, 38]. In addition, our findings 
also suggest a prolonged period of antidiabetic activity that could be attributed to several sites of 
activity possessed by the active principles of T. foenum-graecum.  
Earlier, it was reported that the seed powder of T. foenum-graecum lowered blood glucose in 
normal and streptozotocin-induced diabetic rats [37]. Our present study in rabbit model also 
substantiates the previous results observed in rats. Herefele and colleagues isolated 
galactomannan and 4-hydroxy isoleusine, an insulin releasing substance from the seeds that 
appears to be responsible for the hypoglycaemic effect of T. foenum-graecum [39]. Additionally, 
another potential action mechanism of T. foenum-graecum is an effect on the digestion of 
intestinal carbohydrate, as shown by the strong inhibitory effect on the digestive enzymes [40, 
41]. 
Alloxan, a beta-cytotoxin induces significant death of pancreatic -cells leading to decreased 
synthesis and release of insulin [42-44]. Sulphonylureas are well known to cause hypoglycaemia by 
increasing insulin secretion from the pancreas [45, 46] and these compounds are active in mild 
diabetes induced by alloxan while they are inactive in intense alloxan diabetes (nearly all -cells 
were destroyed). Since our findings have shown that glibenclamide has decreased blood glucose 
levels in hyperglycemic animals, diabetes status is not severe. Alloxan-treated animals receiving 
the seed powder of T. foenum-graecum showed rapid normalisation of blood glucose levels 
relative to control and this may be due to the fact that certain -cells still survive to function on T. 
foenum-graecum to exert its insulin releasing effect. In addition, hypoglycaemia was produced in 
normal animals by oral administration of T. foenum-graecum in the same way as sulphonylureas. 
This indicates that the mode of action of the active ingredients of T. foenum-graecum is possibly 
mediated by an increased insulin secretion, like sulphonylureas. Nevertheless, the likelihood 
increased tissue glucose utilization by T. foenum-graecum cannot be ruled out. It is speculated 
OBM Integrative and Complementary Medicine 2020; 5(3), doi:10.21926/obm.icm.2003036 
 
Page 8/11 
that one or more of the previously isolated bioactive compounds of T. foenum-graecum could be 
responsible for the observed acute lowering of blood glucose. Further work on fractionation, 
purification, identification of active principle(s) and detailed mechanistic evaluation is obviously 
required on the seeds of T. foenum-graecum. 
5. Conclusion  
Our research clearly showed a major anti-diabetic activity with T. foenum-graecum seed 
powder, and supports the traditional use of seed powder for diabetes control. This can also help 
to avoid diabetic complications and act as a strong adjuvant in the new anti-diabetic medication 
armamentarium. 
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